477 related articles for article (PubMed ID: 31018521)
1. Astaxanthin as a Peroxisome Proliferator-Activated Receptor (PPAR) Modulator: Its Therapeutic Implications.
Choi CI
Mar Drugs; 2019 Apr; 17(4):. PubMed ID: 31018521
[TBL] [Abstract][Full Text] [Related]
2. Astaxanthin functions differently as a selective peroxisome proliferator-activated receptor γ modulator in adipocytes and macrophages.
Inoue M; Tanabe H; Matsumoto A; Takagi M; Umegaki K; Amagaya S; Takahashi J
Biochem Pharmacol; 2012 Sep; 84(5):692-700. PubMed ID: 22732454
[TBL] [Abstract][Full Text] [Related]
3. Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt.
Jia Y; Wu C; Kim J; Kim B; Lee SJ
J Nutr Biochem; 2016 Feb; 28():9-18. PubMed ID: 26878778
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.
Chinetti G; Fruchart JC; Staels B
Inflamm Res; 2000 Oct; 49(10):497-505. PubMed ID: 11089900
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
7. Regulation of peroxisome proliferator-activated receptors (PPAR) α and -γ of rat brain astrocytes in the course of activation by toll-like receptor agonists.
Chistyakov DV; Aleshin SE; Astakhova AA; Sergeeva MG; Reiser G
J Neurochem; 2015 Jul; 134(1):113-24. PubMed ID: 25818681
[TBL] [Abstract][Full Text] [Related]
8. Treatment in vitro with PPARα and PPARγ ligands drives M1-to-M2 polarization of macrophages from T. cruzi-infected mice.
Penas F; Mirkin GA; Vera M; Cevey Á; González CD; Gómez MI; Sales ME; Goren NB
Biochim Biophys Acta; 2015 May; 1852(5):893-904. PubMed ID: 25557389
[TBL] [Abstract][Full Text] [Related]
9. The Peroxisome Proliferator-Activated Receptor (PPAR)-
Schubert M; Becher S; Wallert M; Maeß MB; Abhari M; Rennert K; Mosig AS; Große S; Heller R; Grün M; Lorkowski S
Mol Pharmacol; 2020 Mar; 97(3):212-225. PubMed ID: 31871304
[TBL] [Abstract][Full Text] [Related]
10. [Peroxisome proliferator-activated receptor gamma (PPARgamma): molecular study in glucose homeostasis, lipid metabolism and therapeutic approach].
Tavares V; Hirata MH; Hirata RD
Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):526-33. PubMed ID: 17684612
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
Aleshin S; Strokin M; Sergeeva M; Reiser G
Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
[TBL] [Abstract][Full Text] [Related]
12. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
[TBL] [Abstract][Full Text] [Related]
13. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
Becker J; Delayre-Orthez C; Frossard N; Pons F
Fundam Clin Pharmacol; 2006 Oct; 20(5):429-47. PubMed ID: 16968414
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats.
Sun L; Ke Y; Zhu CY; Tang N; Tian DK; Gao YH; Zheng JP; Bian K
Chin Med J (Engl); 2008 Nov; 121(22):2305-11. PubMed ID: 19080338
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
Sertznig P; Seifert M; Tilgen W; Reichrath J
Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
[TBL] [Abstract][Full Text] [Related]
16. PPAR Ligands Containing Stilbene Scaffold.
Fantacuzzi M; De Filippis B; Amoroso R; Giampietro L
Mini Rev Med Chem; 2019; 19(19):1599-1610. PubMed ID: 31161987
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptors control p38 and JNK MAPK signaling pathways in rat astrocytes differently, when cultured in normal or high glucose concentrations.
Chistyakov DV; Azbukina NV; Astakhova AA; Polozhintsev AI; Sergeeva MG; Reiser G
Neurochem Int; 2019 Dec; 131():104513. PubMed ID: 31369777
[TBL] [Abstract][Full Text] [Related]
18. PPARs as therapeutic targets in cardiovascular disease.
van Bilsen M; van Nieuwenhoven FA
Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
Takada I; Makishima M
Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
[No Abstract] [Full Text] [Related]
20. Marine Natural and Nature-Inspired Compounds Targeting Peroxisome Proliferator Activated Receptors (PPARs).
D'Aniello E; Amodeo P; Vitale RM
Mar Drugs; 2023 Jan; 21(2):. PubMed ID: 36827130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
